Search

Volpara Health, a global leader in AI-powered breast health solutions, has achieved a milestone of 300 peer-reviewed scientific papers, demonstrating its commitment to advancing breast cancer detection and personalized care. The company's technology has earned trust within academic and clinical communities, with studies showing improvements in radiologist performance and the identification of women at higher risk for missed cancers. Volpara's dedication to scientific rigor and innovation over 15 years underscores its mission to enhance breast health through AI technology. [Extracted from the article]

The article from Cancer Weekly discusses the initial results of the REFLECTION study by GRAIL, Inc., which focuses on the real-world experience of the Galleri multi-cancer early detection (MCED) test in routine clinical settings. The study included a diverse population of veterans from U.S. Department of Veterans Affairs (VA) sites with toxic exposure but no cancer symptoms. Initial findings showed a cancer signal detection rate of 1.30% among the veteran cohort, with more than half of the identified cases being at early stages. The study aims to address the unmet medical need for cancer screening, especially among veterans at elevated risk. [Extracted from the article]

Volpara Health, a global leader in cancer detection software, is advocating for the bipartisan "Find It Early Act" to improve breast cancer screening. The bill aims to remove financial barriers for women, especially those with dense breast tissue, by requiring insurers to cover advanced imaging like ultrasound and MRI without out-of-pocket costs. Volpara Health's CEO, Teri Thomas, emphasizes the importance of early detection in saving lives and reducing long-term financial burdens on families and the healthcare system. The company's AI-driven tools, like Volpara True Density(R), play a crucial role in assessing breast density accurately. [Extracted from the article]

Kience, a company based in Barcelona, has presented the results of a validation study for its non-invasive test that can detect multiple types of cancer. The test, which uses a blood and urine sample, is designed for individuals aged 40 and over and can screen for up to 42 different types of solid tumors and 5 hematological malignancies. The test is claimed to be less invasive, more economical, and more accurate than other tests on the market, thanks to a machine learning algorithm that incorporates the Barcelona Criteria, established by Dr. Rafael Molina and the Spanish Society of Clinical Chemistry. The company is now conducting a larger clinical trial to further improve the accuracy of the algorithm. [Extracted from the article]

Syantra, Inc., a precision biotechnology company, has raised $4.9 million in Series A-1 funding to accelerate the clinical validation and commercialization of its breast cancer detection test. The funding was provided by CG Wealth Management and existing investors. Syantra's test, which has received regulatory approvals, measures gene expression biomarkers from whole blood and has shown 92% clinical accuracy in blinded clinical studies. The company has also added Dr. Rick Mangat, a medical device executive, to its Board of Directors. These developments come after Cornell University and the University of Calgary received funding from the U.S. Department of Defense for a clinical study on Syantra's blood test for breast cancer detection. [Extracted from the article]

The article discusses the Florida State University Family Medicine Residency Program and its efforts to improve primary care skin cancer detection. It highlights the importance of early detection and the prevalence and costs of skin cancer treatment in the United States. The article also mentions DermaSensor Inc., a company involved in cancer detection. This information may be useful for library patrons researching skin cancer, oncology, and health and medicine. [Extracted from the article]

GRAIL, Inc. has published detailed findings of its Galleri multi-cancer early detection (MCED) test in prostate cancer in JCO Precision Oncology. The data from the study support the clinical performance of the Galleri test in screening for aggressive prostate cancer while minimizing the risk of overdiagnosis of slow-growing cancers. The analysis showed that the MCED test detected mostly clinically significant prostate cancers, with high accuracy in predicting the cancer signal origin. These findings suggest that the Galleri test can be a valuable tool in detecting biologically significant prostate cancers without contributing to the burden of overdiagnosis. [Extracted from the article]

A recent study published in Cancer Weekly discusses the use of surrogate endpoints in cancer screening trials. The study highlights the challenges of conducting large-scale and expensive trials for the development of new screening tests. The researchers propose using surrogate endpoints, which are earlier indicators of the ultimate endpoint of interest, cancer mortality. However, validating surrogate endpoints is a complex task. The study explores potential candidates for surrogate endpoints and provides insights from the therapeutic trial setting. This research has been peer-reviewed and can be found in The Lancet Oncology. [Extracted from the article]

Esophageal cancer is a significant public health challenge in China, ranking sixth in incidence and fifth in mortality among cancers. Late diagnosis is common due to the lack of symptoms in early-stage cancer. Screening efforts have been focused on high-risk areas since 2005, primarily using endoscopy. Early detection through screening is crucial for improving patient survival rates and quality of life. Risk factors for esophageal cancer in China include smoking, alcohol consumption, poor oral hygiene, and certain dietary habits. Current screening methods include endoscopy, exfoliative cytology, and biomarker detection, but advanced technologies like artificial intelligence-assisted methods and new endoscopic techniques are being explored. These technologies have the potential to improve accuracy and efficiency in diagnosis, but their adoption is limited by cost and technical complexities. Continued development and implementation of advanced screening technologies are necessary to improve early detection rates and patient outcomes. [Extracted from the article]

The Hong Kong Breast Cancer Foundation (HKBCF) is organizing its annual fundraising event, "Pink Walk 2024," on October 20, 2024, at The Peak in Hong Kong. The event aims to raise awareness about breast cancer in Hong Kong and raise funds for the HKBCF's initiatives, including education, breast screening, support for patients, and research. The HKBCF encourages people from all walks of life to participate in the walk and maintain regular exercise for their health. The event will feature a 3.5km route suitable for all ages, and participants are encouraged to dress in pink. Registration is open on the event website. [Extracted from the article]

A patent has been issued for a cytology sampling system and method developed by inventors Jerome K. Grudem Jr. and Jay G. Johnson. The patent, assigned to Covidien LP, aims to improve early detection of cancer by collecting larger cell samples from patient tissue. The system includes a flexible shaft, a brush with bristles, and a position sensor to indicate its location within a patient's airway. The brush can transition between a transport configuration and a deployed configuration, and the bristles are helically disposed along the brush shafts. The patent provides detailed specifications for the cytology tool and sampling system. [Extracted from the article]

A recent report discusses the potential of multicancer early detection (MCED) tests in expanding cancer screening. The report focuses on the DETECT-A trial, which used the CancerSEEK blood test coupled with diagnostic PET-CT to detect cancers that were not identified through standard-of-care (SoC) screening. The study found that most of the cancers detected by CancerSEEK were localized or regional, and many participants with early-stage cancers were able to receive curative-intent treatments. These findings suggest that early cancer detection through MCED tests like CancerSEEK may lead to positive clinical outcomes. [Extracted from the article]

A recent qualitative study conducted in Uganda by the RAND Corporation explored the perspectives of women and their male partners on cervical cancer screening. The study found that only 5% of women in Uganda have been screened for cervical cancer, with barriers such as social stigma and limited access to safe conditions identified as key factors. The research also highlighted the importance of spousal support in promoting screening, although male perspectives varied from full support to hesitancy around male-performed exams. The study emphasizes the need for interventions that address these barriers and facilitators to increase demand for screening and mitigate the burden of cervical cancer. [Extracted from the article]

Herbalife and LA Galaxy recently supported A Place Called Home's annual Back-to-School event in South Central Los Angeles. They donated 1,000 backpacks filled with school supplies and also organized a Community Health and Resource Fair, where attendees had access to essential services such as health and wellness checks, optometry screenings, vaccinations, mammograms, daycare, and workforce registrations. This event aimed to assist South Central Los Angeles youth and their families in preparing for the school year. A Place Called Home is a nonprofit organization that provides free programs in the arts, education, and health and wellness for South Central youth and their families. [Extracted from the article]

A patent has been issued to Grail LLC for methods and systems for screening for conditions. The patent describes methods that use combinations of assays to improve the positive predictive value of tests for detecting tumors. The methods involve performing a first assay to analyze sequencing reads for copy number aberrations, and if a copy number aberration is detected, performing a second assay to screen for biomarkers of the condition. The second assay has a greater read depth than the first assay, resulting in a higher positive predictive value for screening. The patent provides detailed information on the sequencing reads, read depths, and sample types used in the methods. [Extracted from the article]

A patent has been issued to 20/20 GeneSystems Inc. for methods and machine learning systems that predict the likelihood of having cancer. The patent aims to improve cancer screening accuracy and standardization, particularly in regions where it is common, and provide healthcare practitioners with more quantitative information about their patients' likelihood of having cancer. The patent also addresses the challenges of detecting early stage cancer and the limitations of current screening methods, with a focus on the potential of blood tests to complement radiographic screening. The use of artificial intelligence and machine learning systems in medical practice is also discussed. The patent provides specific details on a computer-implemented method for predicting the likelihood of cancer using machine learning and diagnostic tests. [Extracted from the article]

A recent study conducted by IOM Ricerca Srl in Catania, Italy, has developed a novel liquid biopsy method for detecting and characterizing prostate cancer. The current screening methods for prostate cancer have limitations, including poor specificity and invasiveness. The researchers identified specific proteins in extracellular vesicles from the blood of prostate cancer patients that can accurately distinguish between prostate cancer and hyperplasia. This non-invasive liquid biopsy method has the potential to improve prostate cancer screening and diagnosis. [Extracted from the article]

St. Luke's University Health System has been awarded Volpara Health's inaugural "Analytics in Action Designation of Excellence" award for their high-quality mammograms. St. Luke's has implemented Volpara Analytics software and participated in the comprehensive Analytics in Action program to standardize excellence across their breast centers and support staff development. The program uses objective measurements to assess quality and provides personalized training and goal setting. St. Luke's commitment to continuous staff development and delivering the best possible care has earned them this recognition. [Extracted from the article]

A patent application has been submitted by inventors from South Korea for an apparatus and method that interlocks a lesion location between a guide image and 3D tomosynthesis images. The invention aims to improve cancer diagnosis by combining 2D medical images with 3D tomosynthesis images, allowing for more efficient reading of lesions. The apparatus includes a memory and processor that receive and display the guide image and 3D image slices, with the ability to change the displayed image to highlight a specific lesion. This technology has the potential to enhance tumor detection and improve early diagnosis of cancer. [Extracted from the article]

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that it generated $699 million in revenue for the second quarter of 2024, compared to $622 million for the same period in 2023. The company's screening revenue increased by 15 percent, while precision oncology revenue increased by 7 percent. The gross margin was 70 percent, and the net loss improved by $65 million. Exact Sciences Corp. also reported increases in adjusted EBITDA, operating cash flow, and free cash flow. [Extracted from the article]

A recent study conducted by researchers at the RAND Corporation focused on developing recommendations for cervical cancer screening in Malawi, a country with a high burden of cervical cancer and HIV prevalence. The study used a Markov model to compare different approaches to screening, including frequency and treatment methods. The results showed that thermocoagulation was more cost-effective than cryotherapy at all screening frequencies. Additionally, a stratified approach that prioritizes more frequent screening for women living with HIV may be more cost-effective than population-wide recommendations. These findings provide new evidence for cost-effective cervical cancer screening in low-income countries. [Extracted from the article]

GRAIL, Inc. has enrolled the first participant in the REACH/Galleri-Medicare study, which aims to evaluate the clinical impact of the Galleri multi-cancer early detection (MCED) test in Medicare beneficiaries. The study will focus on historically underrepresented communities, including seniors, racial and ethnic minority groups, socioeconomically disadvantaged populations, and rural populations. Over a three-year period, the study will compare up to 50,000 Medicare beneficiaries who receive the Galleri test with a control group that does not. The study will assess reduction in diagnosed stage IV cancers, safety, and healthcare resource utilization. Medicare will cover the costs of the Galleri test for study participants. [Extracted from the article]

Natera Inc. has been issued a patent for methods of cancer detection and monitoring. The patent describes a method for monitoring and detecting early relapse or metastasis of various types of cancer, including breast cancer, bladder cancer, and colorectal cancer. The method involves generating a set of amplicons from nucleic acids isolated from a blood or urine sample, and determining the sequence of each amplicon to detect patient-specific single nucleotide variants associated with cancer relapse or metastasis. The patent claims also include specific details about the method's specificity and sensitivity in identifying minimal residual disease in breast cancer patients. [Extracted from the article]

A patent has been issued to Hepatiq Inc. for a system and method of detecting liver cancer using image data obtained from a functional scanner. The system involves determining a region of interest corresponding to the liver, identifying a suspected tumor mass within that region, and tracking the shape of the tumor over time to confirm its presence. The system can also determine the volume of the tumor and assess organ function parameters. This technology aims to improve the early detection and monitoring of liver cancer, which is a life-threatening disease. [Extracted from the article]

Thermo Fisher Scientific, the National University Hospital (NUH) in Singapore, and Mirxes, a Singapore-based RNA technology company, have signed a Memorandum of Understanding (MoU) to enhance access to affordable genomic testing for cancer in Singapore. The collaboration aims to develop and validate advanced genomic testing solutions tailored to the needs of the Southeast Asian population. The partnership will enable healthcare providers to select the most appropriate therapy for individualized patients, refine early detection methods, and deliver more precise diagnoses and treatments. The NUH Diagnostic Molecular Oncology Centre currently offers next-generation sequencing (NGS) testing for four common cancers and plans to expand access in the region. [Extracted from the article]

This document is a patent for an esophageal cancer detection kit and method. The patent describes a method for detecting esophageal cancer by measuring the expression level of a specific nucleic acid in a blood, serum, or plasma sample. The inventors claim that their method can effectively detect esophageal cancer and guide appropriate treatment or diagnostic procedures. The patent also mentions existing diagnostic tests and treatments for esophageal cancer. The document provides keywords related to the topic, including surgery, genetics, oncology, biomarkers, and cancer detection. [Extracted from the article]

A report discusses research findings on cancer, specifically the impact of multi-cancer early detection (MCED) tests on patient-reported outcomes (PRO) and behavioral intentions. The study included a survey of the general population and a clinical trial. Results showed that a negative MCED test result was associated with positive cancer screening intentions and other preventive healthcare behaviors. It also had a positive impact on psychological and emotional health. However, further research is needed to understand the behavioral impact of MCED screening. [Extracted from the article]

Researchers at Global Health Labs Inc. have conducted a study on cervical cancer screening in Zambia. They developed an artificial intelligence-based tool called Automated Visual Evaluation (AVE) that can assess smartphone-captured images of the cervix and identify precancerous lesions. The study found that AVE performed well in identifying cervical precancerous and cancerous lesions, with a sensitivity of 85% and specificity of 86%. The researchers concluded that AVE shows promise as a screening tool and further evaluation is needed. However, the study has limitations, including potential bias and internal validation. [Extracted from the article]

Guardant Health Inc. has been issued a patent for a method and system to detect and monitor cancer evolution. The patent describes a computer-implemented method that uses genetic profiles of tumors obtained from cell-free bodily fluids to predict patient response and emerging resistance to cancer treatment. The method involves obtaining information about subjects with cancer at different time points, determining their states based on this information, and using this data to generate a predictive algorithm. The algorithm calculates the probability of a given state leading to another state at a later time point. The patent also mentions the use of decision trees and machine learning algorithms in the process. This technology aims to provide alternative tools for predicting patient response and resistance to cancer treatment. [Extracted from the article]

A recent study conducted by Berry Oncology Corporation in Beijing, China, has developed a new multi-cancer early detection (MCED) test called HIFI-PROF. The test utilizes extremely low pass whole-genome sequencing to detect and localize six types of cancer (colorectal, pancreas, liver, lung, esophagus, and gastric cancer). The study included 1,487 participants and achieved a sensitivity of 87.58% and a specificity of 99.09% in detecting multiple cancer types. The researchers concluded that HIFI-PROF offers a cost-effective MCED test with excellent performance, which could lead to more effective clinical interventions and better outcomes. [Extracted from the article]

A recent study conducted by Health Advances LLC explored the barriers to the widespread adoption of blood-based multi-cancer early detection (MCED) tests. The research found that while there is broad agreement on the value of these tests, their limited use is due to concerns about clinical accuracy and utility data, high patient costs, and lack of payer coverage. To overcome these barriers, the study suggests increased investment in data generation, education, and logistical support for healthcare providers. The findings highlight the potential of MCED tests to improve cancer screening and early detection beyond the current recommendations for breast, cervical, colorectal, and lung cancer. [Extracted from the article]

A researcher from Hamad Medical Corporation (HMC) has published new studies and findings on genomic newborn screening for pediatric cancer predisposition syndromes. The research highlights the importance of next-generation sequencing (NGS) in identifying germline and rare genetic variations responsible for inherited illnesses, including cancer predisposition syndromes. The study discusses the clinical and molecular characteristics of various syndromes, as well as ethical issues, challenges, and limitations in conducting germline genetic diagnostic studies in children with cancer. The research suggests that genomic newborn screening could be a practical and cost-effective strategy in pediatric cancer care. [Extracted from the article]

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced its first-quarter 2024 results. The company generated revenue of $638 million for the quarter, compared to $602 million for the same period in 2023. The increase in revenue was attributed to the delivery of over a million Cologuard and Oncotype DX test results to patients, as well as advancements in their pipeline of cancer diagnostics. The company aims to expand its portfolio globally and continue its mission to help eradicate cancer. [Extracted from the article]

Toray Industries Inc. has been issued a patent for a prostate cancer detection kit and method. The patent describes a method for detecting prostate cancer by measuring the expression level of a specific microRNA, hsa-miR-6741-5p, in a blood, serum, or plasma sample. The decreased level of hsa-miR-6741-5p indicates the presence of prostate cancer. This method can be used to guide treatment decisions and diagnostic procedures for prostate cancer. The patent also includes details on the diagnostic procedure and the device used for measuring microRNA expression levels. The patent was filed by Junpei Kawauchi and assigned to Toray Industries Inc. [Extracted from the article]

Dr. Gregory C. Critchfield, Co-CEO of EarlyDiagnostics, Inc., has been awarded the State of Utah's Governor's Medal for Science and Technology for his contributions to the industry. With over 30 years of experience in diagnostics, Dr. Critchfield joined EarlyDiagnostics in January 2024 to lead the development of accurate and affordable liquid biopsy tests for early cancer detection. The company is set to launch novel commercial products this year, utilizing proprietary chemistries and advanced AI bioinformatics. Dr. Critchfield's expertise and leadership are expected to drive EarlyDiagnostics to the forefront of early cancer detection and personalized medicine. [Extracted from the article]

SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, presented new data at the American Association for Cancer Research (AACR) Annual Meeting in San Diego. The data included three additional validation studies that demonstrated OncoSeek's ability to detect over nine types of cancer and predict the tissue of origin using a blood sample. The results were consistent across different cohorts and platforms, indicating the generalizability of OncoSeek's capabilities. OncoSeek has the potential to be a low-cost and effective cancer early detection and diagnosis technology, particularly in low- and middle-income countries. [Extracted from the article]

Freenome, a biotechnology company, has announced the topline results of its blood-based test for the early detection of colorectal cancer (CRC). The test demonstrated 79.2% sensitivity in detecting CRC and 91.5% specificity for non-advanced colorectal neoplasia. It also showed 12.5% sensitivity in detecting advanced adenomas. The study involved over 48,000 asymptomatic, average-risk adults and utilized a hybrid model to reach underserved communities. Freenome plans to continue innovating and improving the test based on these results. [Extracted from the article]

A patent application has been submitted for a breast cancer detection kit and method that aims to find new tumor markers for breast cancer. The current diagnostic tests for breast cancer have limitations, and existing tumor markers are not effective for early detection. The authors propose a method for detecting breast cancer by measuring the expression level of miR-6757-5p in a blood sample, with increased levels indicating the presence of breast cancer. The patent application also mentions a kit that can be used to measure the expression levels of other breast cancer markers. The text provides additional information on the invention and its potential applications. [Extracted from the article]

Breast cancer is a common and serious health concern for women, with treatment and prognosis varying due to the heterogeneity of the disease. Chemotherapy is currently the main treatment for triple-negative breast cancer (TNBC), but it often has suboptimal efficacy. In a study published in the journal Biomedical Analysis, Chinese researchers propose a new approach using a dual-miRNA triggered DNA nanomachine that can detect specific breast cancer subtypes and regulate drug release for chemotherapy. This nanomachine offers a tailored treatment strategy that reduces side effects and facilitates targeted therapy, showing promise as a theranostics nanoplatform in precise medicine. [Extracted from the article]

Glassbeam Inc. has been issued a patent for a system that predicts medical device failure based on operational log data. The system uses statistical and machine learning techniques to determine if a part needs to be replaced before it fails. It can transform the subset of logged event data into a normalized form and train a machine learning model to predict failure of the target part in a device. This technology has potential applications in various medical devices, including medical imaging devices. [Extracted from the article]

Olympus Corporation of the Americas, a global medical technology company, has partnered with the American Lung Association to provide educational resources for lung cancer patients. The resources aim to help patients understand the diagnosis and staging process for lung nodules, empowering them to make informed decisions about their care. Olympus' technology, including endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), has played a role in targeted cancer treatment and immunotherapy. Early detection of lung cancer is crucial, as the survival rate significantly decreases once the cancer spreads. Olympus is proud to support this patient education campaign to promote early diagnosis and treatment. [Extracted from the article]

A patent application has been submitted by inventors from Canon Medical Systems Corporation for an apparatus, method, and computer-readable storage medium that aims to improve image quality in medical imaging systems. The invention focuses on generating a task-aware dynamic sparse-view scanning procedure, which can reduce radiation exposure while maintaining image quality. The method involves acquiring CT volume image data, extracting simulated projections, and determining a sparse subset of these projections that, when reconstructed, produces optimized image quality and radiation dosage. The invention also includes an imaging apparatus and a method for determining imaging conditions using a trained neural network. [Extracted from the article]

A patent application by Shanghai United Imaging Intelligence Co. LTD. describes a system and method for magnifying medical images based on trained neural networks. The system includes a hardware processor that receives user inputs for selecting a region of interest (ROI) and a magnification factor. The ROI is then modified using a neural network model to create a magnified image, which is displayed on a display device. The invention aims to improve the visualization of ROIs in medical diagnostic imaging techniques, such as mammography, to aid in cancer diagnosis. [Extracted from the article]

A recent study published in Cancer Screening and Prevention assessed the prevalence of colorectal cancer (CRC) and premalignant lesions in the colon in OSI Araba. The study included individuals aged 50-69 who were admitted to OSI Araba Health Centers and spanned from 2009 to 2021. The results showed that CRC screening is an effective strategy in reducing incidence and mortality rates. The study suggests the possibility of implementing improved strategies, such as risk algorithms and adjusting cut-off points, and highlights the importance of primary care physicians in promoting prevention. [Extracted from the article]

A patent has been issued to Tencent Technology (Shenzhen) Company Limited for a mammographic image processing method and apparatus. The invention aims to improve the accuracy of breast cancer screening by using a computer device to analyze mammographic images and generate a detection report. The method involves recognizing gland types, predicting the condition of the breast, and performing lesion detection. The patent describes the use of neural networks and other models to enhance the accuracy of the diagnosis. This technology has the potential to improve early detection and treatment of breast cancer. [Extracted from the article]

Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) are emphasizing the importance of preventive cancer screenings and knowing one's family health history, particularly in light of the increasing death rates from colorectal cancer among patients under the age of 50. Colorectal cancer is now the leading cause of cancer death for men under 50 and the second leading cause for women under 50. The U.S. Preventive Services Task Force (USPSTF) has lowered the recommended screening age for those at average risk of colorectal cancer from 50 to 45. Screening options include colonoscopy and fecal immunochemical tests (FIT), and it is important for individuals to discuss these options with their primary care providers (PCPs). Early detection is crucial, as the survival rate is significantly higher when colorectal cancer is caught at an early stage. Olympus technologies, such as Texture and Color Enhancement Imaging (TXI) technology, are helping improve adenoma detection rates during screenings. However, it is essential for patients to properly prepare for their colonoscopies to ensure the best results. [Extracted from the article]

Olympus Corporation of the Americas (OCA) has emphasized the importance of allyship in promoting equitable access to healthcare for all communities, particularly during Black History Month. As a leading provider of equipment used for colon cancer screening, diagnosis, and treatment, Olympus supports and advocates for equitable access to preventive health screenings like colonoscopy for Black Americans. The company's African American Employee Resource Group (ERG) plays a crucial role in promoting screening and early cancer detection. Colon cancer statistics highlight the need for increased awareness, education, and access to screenings, as Black Americans have higher death rates and are less likely to get screened. Olympus encourages Black Americans and their allies to prioritize health and screening and to communicate the importance of health and wellness to employers and family members. [Extracted from the article]

A patent has been issued to 4D Path Inc. for an apparatus, systems, and methods for rapid cancer detection. The invention aims to address the shortcomings of current cancer detection methods by analyzing metabolic imprints of cells for cancer detection. The methods and systems involve extracting thermal and thermodynamic quantities from the molecular imprints of cells and mapping them on a universal cancer diagnostic scale. This patent provides improved methods for detecting cancer with high specificity and sensitivity. [Extracted from the article]